#USA #Philadelphia #Nuvation Bio #safusidenib #IDH1-Mutant

Nuvation Bio Unveils Updated Phase 2 Data

Nuvation Bio Inc. (NYSE: NUVB), recognized as a global leader in oncology, is set to present significant updates at the Society for Neuro-Oncology (SNO) Annual Meeting scheduled for November 12-15, 2026, in Philadelphia, PA. The company’s ongoing efforts in the treatment of IDH1-mutant gliomas are underscored by their ongoing trials and the anticipated presentation of four distinct posters.

Among these, one poster will provide a comprehensive overview of updated long-term results from the Phase 2 J201 study, while the other three will focus on ongoing trials involving safusidenib, their investigational drug targeting the mutant IDH1 enzyme.

In a previous announcement made in July 2026, Nuvation Bio revealed promising topline results from their Phase 2 J201 study. However, the upcoming presentation will offer additional crucial data that builds upon those early findings. David Hung, M.D., the company’s Founder, President, and CEO, noted that patients with IDH1-mutant gliomas often receive their diagnoses in their 30s and 40s, stressing the necessity of targeted therapies that can not only prolong life but also maintain a consistent safety profile.

This sentiment resonates strongly within the scientific community, as the need for reliable treatments in this demographic becomes increasingly evident. The following is a summary of the presentations lined up for the meeting:

1. Updated Efficacy and Safety Results of Safusidenib in Chemotherapy and Radiotherapy-Naïve Grade 2 IDH1-Mutant Glioma
- Presenter: Yoshiki Arakawa (Kyoto University Graduate School of Medicine, Japan)
- Date: November 13, 2026
- Session Time: 7:30-9:30 p.m. ET

2. SIGMA: A Phase 3 Study Evaluating Safusidenib vs Placebo Following Radiotherapy and Adjuvant Temozolomide in Patients with IDH1-Mutant Astrocytoma
- Presenter: Katherine B. Peters (Duke University Medical Center, Durham, USA)
- Date: November 13, 2026
- Session Time: 7:30-9:30 p.m. ET

3. Open-label, Single-arm, Exploratory Cohort Evaluating Safusidenib in Grade 3 IDH1-Mutant Oligodendroglioma
- Presenter: Fabio Iwamoto (Columbia University Irving Medical Center, New York, USA)
- Date: November 13, 2026
- Session Time: 7:30-9:30 p.m. ET

4. Phase 2 Study Evaluating Safusidenib's Efficacy and Safety after Disease Progression on Vorasidenib
- Presenter: Macarena de la Fuente (Sylvester Comprehensive Cancer Center, University of Miami, USA)
- Date: November 13, 2026
- Session Time: 7:30-9:30 p.m. ET

Following the presentation, full materials will be accessible on Nuvation Bio's website, further enlightening future discussions surrounding IDH1-mutant glioma treatments.

Understanding IDH1-Mutant Glioma

Gliomas rank as the most prevalent form of brain cancer among adults globally, with nearly 2,500 new IDH-mutant glioma diagnoses each year in the U.S. Surprisingly, over 95% of these cases involve an IDH1 gene mutation. The statistical survival advantage for patients with IDH1 mutations is overshadowed by the reality that gliomas remain incurable, with particularly grim prognoses for those presenting high-risk characteristics.

About Safusidenib

Safusidenib represents an innovative oral therapy designed to penetrate brain tissue and specifically inhibit mutated IDH1. Its development is aimed at addressing the considerable unmet medical need in brain cancer therapy. Clinical findings from earlier phases of trials indicate notable efficacy, such as delays in disease progression and sustained responses across various tumor grades, reinforcing the drive for ongoing projects like the Phase 3 SIGMA study.

Nuvation Bio’s Mission

Founded in 2018 by prominent biopharma expert David Hung, M.D., Nuvation Bio is devoted to overcoming substantial challenges in cancer therapeutics. Their pipeline is diverse, featuring various investigational drugs like taletrectinib (IBTROZI®) and safusidenib combined with a robust drug-drug conjugate program aimed to make a meaningful impact on patient lives. Follow them on LinkedIn and X (@nuvationbioinc) for updates on their groundbreaking work.